Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 study of Sanofi's amcenestrant vs tamoxifen for women with estrogen receptor-positive (ER+) breast cancer

Next Previous
X
Search
Trial Profile

Phase 3 study of Sanofi's amcenestrant vs tamoxifen for women with estrogen receptor-positive (ER+) breast cancer

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 20 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amcenestrant (Primary) ; Tamoxifen
  • Indications Breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms AMEERA-6
  • Sponsors Sanofi

    • Most Recent Events

    • 17 Aug 2022 According to a sanofi media release, the company has decided to discontinue global clinical development program of amcenestrant based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial.
    • 17 Aug 2022 Status changed from recruiting to discontinued, according to a sanofi media release.
    • 14 Mar 2022 Status changed from planning to recruiting, according to a Sanofi media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top